Real Patient Stories

Real patients, real stories

Hear real stories from DUPIXENT patients and learn about what made them turn to DUPIXENT

DUPIXENT was the treatment choice for these patients with uncontrolled moderate-to-severe atopic dermatitis.

patients have filled at least 1 DUPIXENT prescription.1,a,b Check out the stories of 2 adult and 2 adolescent patients who started DUPIXENT to help manage their disease.


a IQVIA National Source of Business (NSOB) data as of October 2020.

b New patients with atopic dermatitis (6 years and older).

Adults, aged 18+

CLINICAL TRIAL RESULTS IN ADULTS AND TRIAL DESIGNS

Currently taking DUPIXENT

I was in bad shape before starting DUPIXENT. Now, I feel like I have control over my disease.

Real patient treated
with DUPIXENT.
Individual results
may vary.

Her signs and symptoms

  • Living with eczema since childhood, but symptoms became worse in her mid-20s
  • Experienced regular itching, redness, dry skin, and scaliness
  • Symptoms primarily occurred on elbows, neck, face, feet, and arms

Her treatment and goals

  • Tried countless over-the-counter medications, topical Rx, and oral steroids with limited, short-term success
  • Desperate to find a treatment with lasting relief
  • Finding a treatment to reduce the severity of her disease is most important to her

Currently taking DUPIXENT

I don’t want to be defined by my atopic dermatitis. Since starting DUPIXENT, I don’t feel held back.

Real patient treated
with DUPIXENT.
Individual results
may vary.

His signs and symptoms

  • Itchy, flaky skin across his arms and legs
  • Physical activity leads to sweat irritation and skin dryness
  • Describes his itch as feeling like poison ivy that won’t go away

His treatment and goals

  • Tried a variety of prescription medications, topical and oral steroids, moisturizers, and holistic medicines with little success
  • Needs an atopic dermatitis treatment to relieve the persistent itch
  • Willing to try anything to break the cycle of itchiness and redness that has plagued him for 30+ years

Adolescents, aged 12-17

CLINICAL TRIAL RESULTS IN ADOLESCENTS AND TRIAL DESIGN

Currently taking DUPIXENT

Since trying DUPIXENT, my skin has been clearing up and I feel less itchy.

Real patient treated
with DUPIXENT.
Individual results
may vary.

Her signs and symptoms

  • Itchy and irritated skin over most of her body
  • Open cracks on her hands during dry weather
  • Some of her favorite activities, such as gymnastics and beach volleyball, cause severe itching
  • Scratching all day and night
  • Concerned about her skin’s appearance and how it's perceived by others in school
  • Previous medicines did not provide adequate control, leading to discontinuation

Her treatment and goals

  • She worked with her doctor over the years trying home remedies, steroids, and other prescription therapies with limited, short-term success
  • Looking for a treatment with an efficacy and safety profile that is right for her

Currently taking DUPIXENT

With DUPIXENT, I don't have that intense itching.

Real patient treated
with DUPIXENT.
Individual results
may vary.

His signs and symptoms

  • Experienced dry patches, scabbed and irritated skin
  • Found that the constant itch affected his ability to play sports and enjoy physical activities
  • Frustration with persistent itch throughout the day and night

His treatment and goals

  • Has tried home remedies, topicals, and immunosuppressants and remained uncontrolled
  • Found that previous treatments did not provide adequate control, leading to discontinuation
  • Wanted a treatment where administration can be incorporated into his lifestyle

References:

  1. Data on file, Regeneron Pharmaceuticals, Inc.
  2. DUPIXENT Prescribing Information
  3. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  4. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  5. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44-56.

Important Safety
Information and Indication

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Atopic Dermatitis Patients with Comorbid Asthma: Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥1% at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. Healthcare providers and patients may call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/ to enroll in or obtain information about the registry. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.

Indication

DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.